Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Imipramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 15/20 | 0.60 |
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | HRH1 | P35367 | 4/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.60 |
| ▸ | DRD2 | P14416 | 3/20 | 0.60 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.60 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.60 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.60 |
| ▸ | HTR2A | P28223 | 3/20 | 0.60 |
| ▸ | HTR2C | P28335 | 3/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.60 |
| ▸ | DRD3 | P35462 | 3/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pamoic Acid SCHEMBL21834068 | 0.84 | SLC6A4 (0.56) | LMNAMAPTKDM4EPMP22SMN1; SMN2 | |
| Pamoic Acid SCHEMBL41090 | 0.84 | SLC6A4 (0.56) | LMNAMAPTKDM4EPMP22SMN1; SMN2 | |
| Imipramine SCHEMBL4283852 | 0.83 | SLC6A4 (0.71) | LMNAMAPTKDM4EPMP22SMN1; SMN2 | |
| Imipramine SCHEMBL20644144 | 0.81 | SLC6A4 (0.83) | LMNAMAPTKDM4EPMP22SMN1; SMN2 | |
| Pamoic Acid SCHEMBL517502 | 0.80 | SLC6A4 (0.51) | LMNAMAPTKDM4EPMP22SMN1; SMN2 | |
| Imipramine SCHEMBL28759733 | 0.79 | LMNA (1.00) | LMNAMAPTKDM4EPMP22SMN1; SMN2 | |
| Imipramine SCHEMBL41765 | 0.79 | LMNA (1.00) | LMNAMAPTKDM4EPMP22SMN1; SMN2 | |
| Imipramine SCHEMBL41766 | 0.79 | LMNA (1.00) | LMNAMAPTKDM4EPMP22SMN1; SMN2 | |
| Imipramine SCHEMBL2099292 | 0.79 | LMNA (0.77) | LMNAMAPTKDM4EPMP22SMN1; SMN2 | |
| Pamoic Acid SCHEMBL16222836 | 0.78 | SLC6A4 (0.63) | LMNAMAPTKDM4EPMP22SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163790-B2 | Metronidazole cocrystals and imipramine cocrystals | New Form Pharmaceuticals, Inc. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20090258859-A1 | METRONIDAZOLE COCRYSTALS AND IMIPRAMINE COCRYSTALS | SSCI, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| EP-1962600-A2 | METRONIDAZOLE COCRYSTALS AND IMIPRAMINE COCRYSTALS | SSCI, Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007067727-A2 | METRONIDAZOLE COCRYSTALS AND IMIPRAMINE COCRYSTALS | SSCI, INC. (US) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258859-A1 | METRONIDAZOLE COCRYSTALS AND IMIPRAMINE COCRYSTALS | GCDH, ME2, FH | SLC6A4 669/4885SLC6A2 310/4885LMNA 2035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.